John Maraganore

John Maraganore, founding CEO of Alnylam Pharmaceuticals who led development of RNA interference therapeutics. He recounts the long road to creating a new drug class. Topics include RNAi delivery challenges, strategic use of LNPs and GalNAc conjugates, target selection and rare-disease commercial strategy, clinical setbacks and recoveries, partnerships that validated the approach, and how computation and AI are accelerating discovery.

John Maraganore, the founding CEO of Alnylam Pharmaceuticals, shares his inspiring journey from a Greek immigrant family to a biotech legend. He reveals how a serendipitous lab experience led him to create bivalirudin and pivot into business. John discusses challenges in advancing RNAi therapies, targeting TTR amyloidosis, and maintaining team morale during tough times. His insights offer valuable lessons for entrepreneurs and scientists alike, emphasizing resilience, optimism, and a patient-focused approach to innovation.

John Maraganore, a biotech veteran and former CEO of Alnylam Pharmaceuticals, talks about his startup City Therapeutics and recent Nobel Prize awards. He touches on the evolution of RNA interference and its entrepreneurial challenges. Megan Molteni, a STAT reporter, dives into He Jiankui's controversial work and his new cryptocurrency backer, discussing the ethical implications of gene editing. The conversation also explores the ongoing debates around AI's future, capturing both optimistic and pessimistic perspectives in tech.